DCC4968 |
Suku-33 |
Novel potent inhibitor of osteoclastogenesis, suppressing both equilibrative nucleoside transporters and concentrative nucleoside transporters |
|
DCC4969 |
Sul-121 Hydrochloride |
Novel inhibitor of airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease (COPD) |
|
DCC4970 |
Sulfacetamide |
Antibacterial, inhibiting bacterial folic acid synthesis by competing with para amino benzoic acid |
|
DCC4971 |
Sulfazecin |
β-Lactam antibiotic against multi-drug resistant pathogens |
|
DCC4972 |
Sulfonyl Quinoxaline 1 |
Novel inhibitor of RhoG-hepcidin uptake |
|
DCC4973 |
Sulfosuccinimidyl Oleate Sodium |
Neuroprotective agent, alleviating stroke-induced neuroinflammation |
|
DCC4974 |
Suloctidil Hydrochloride |
Peripheral vasodilator |
|
DCC4975 |
Sulukast |
Novel, potent, selective, and competitive antagonist of LTD4 and LTE4 |
|
DCC4976 |
Sumanirole |
D2 selective dopamine agonist, showing anxiolytic and anti-parkinsonian activities |
|
DCC4977 |
Sun13837 |
Novel fibroblast growth factor receptor modulator for treating neurodegenerative diseases |
|
DCC4978 |
Sun-c5174 |
5-HT2 antagonist |
|
DCC4979 |
Supradamal |
Potent Inhibitor of Plasmodium FK506 Binding Protein 35 (FKBD35), also act as a HIV inhibitor |
|
DCC4980 |
suvanine |
Antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR) |
|
DCC4981 |
Sv-293 |
Selective D2 dopamine receptor antagonist |
|
DCC4982 |
Sv-iii-130s |
D2 dopamine receptor partial agonist in adenylyl cyclase inhibition assay and antagonist in the GIRK and phospho ERK1/2 assays |
|
DCC4983 |
Sw208108 |
Novel clickable tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD) |
|
DCC4984 |
Swainsonine |
Natural potent alpha-mannosidase inhibitor, exhibiting antimetastatic, antiproliferative, and immunomodulatory activities |
|
DCC4985 |
swertisin |
Potent differentiating agent |
|
DCC4986 |
S-y048 |
Novel selective OXE receptor antagonist |
|
DCC4987 |
Sy-5609 |
Novel highly potent and selective CDK7 inhibitor, demonstrating broad anti-tumor activity in vivo |
|
DCC4988 |
Syk-524 |
Novel universal opioid receptor agonist |
|
DCC4989 |
Syk-in-ii |
Novel inhibitor of the Syk kinase (spleen tyrosine kinase) |
|
DCC4990 |
Syn-1 Peptide |
Novel potent and specific inhibitor of syncytin-mediated cell fusion, completely blocking cell fusion at 1.6 μg/ml |
|
DCC4991 |
Syn-1 Scr Peptide |
Negative control of Syn-1 peptide, having the same amino acid composition as Syn-1 peptide, but a scrambled sequence |
|
DCC4992 |
syn22269076 |
Novel Mycobacterium tuberculosis growth inhibitor |
|
DCC4993 |
Synstab A |
Novel microtubule-stablizer |
|
DCC4994 |
Synthalin Dihydrochloride |
K+ channel blocker |
|
DCC4996 |
Szv558 |
Potent inhibitor of both rodent and human MAO-B, proved to be safe in high doses with no hERG and mutagenic activities and demonstrated neuroprotection in an in vivo chronic model of PD |
|
DCC4997 |
T0511-4424 |
Novel COX-2 inhibitor |
|
DCC4998 |
T-0632 |
Potent and selective CCKA receptor antagonist |
|